Literature DB >> 4734403

The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.

C A Alper, I Goodkofsky, I H Lepow.   

Abstract

Factor B activity of the properdin system was found to be identical with purified glycine-rich beta-glycoprotein (GBG) but was distinct from the normal human serum protein capable of forming a C3-inactivating complex with a protein from cobra venom (CoF). Factor B activity coincided with electrophoretically separated GBG genetic variants, whereas the CoF-binding protein did not. GBGase destroyed factor B as it cleaved GBG but did not destroy the C3-inactivating activity of the CoF-binding protein. During incubation of serum with CoF, GBG did not change in molecular size, nor was there any coincidence in the immunoelectrophoretic mobilities of CoF and GBG. It was not possible to precipitate labeled CoF incubated with serum by anti-GBG, nor labeled GBG from serum incubated with CoF by anti-CoF. The CoF-binding capacity of serum was 2 mg/100 ml or less or under 6.5% of the serum concentration of GBG. When labeled CoF was added to serum below the binding capacity, complete complexation of the CoF was demonstrated, whereas CoF was largely uncomplexed when CoF was added in amounts equimolar to GBG.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4734403      PMCID: PMC2139488          DOI: 10.1084/jem.137.2.424

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  A new supporting medium for preparative electrophoresis.

Authors:  H J MULLER-EBERHARD
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

2.  The properdin system and immunity. XIII. Assay and properties of a heat-labile serum factor (factor B) in the properdin system.

Authors:  L BLUM; L PILLEMER; I H LEPOW
Journal:  Z Immun exp ther       Date:  1959 Oct-Nov

3.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

4.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

5.  Isolation and properties of a glycine-rich gamma-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-07-27

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  The properdin system and immunity. V. The bactericidal activity of the properdin system.

Authors:  A C WARDLAW; L PILLEMER
Journal:  J Exp Med       Date:  1956-05-01       Impact factor: 14.307

8.  Genetic polymorphism of the third component of human complement (C'3).

Authors:  C A Alper; R P Propp
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

9.  SNAKE VENOM IN RELATION TO HAEMOLYSIS, BACTERIOLYSIS, AND TOXICITY.

Authors:  S Flexner; H Noguchi
Journal:  J Exp Med       Date:  1902-03-01       Impact factor: 14.307

10.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  14 in total

1.  C3 proactivator (C3PA) as an acute phase reactant.

Authors:  M Schutte; R DiCamelli; P Murphy; M Sadove; H Gewurz
Journal:  Clin Exp Immunol       Date:  1974-10       Impact factor: 4.330

Review 2.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

3.  Complete absence of the third component of complement in man.

Authors:  M Ballow; J E Shira; L Harden; S Y Yang; N K Day
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

4.  Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus.

Authors:  M A Schrager; N F Rothfield
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

5.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

6.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  The use of antibody-coated liposomes as a target cell model for antibody-dependent cell-mediated cytotoxicity.

Authors:  B Geiger; A D Schreiber
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

Review 8.  Properdin: approaching four decades of research.

Authors:  K K Maves; J M Weiler
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

9.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

10.  Properdin: initiation of alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.